Abstracts tagged "abatacept and treatment"

Abstract Number: 2414 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial
Jolien van Nimwegen¹, Esther Mossel ¹, Robin Wijnsma ¹, Greetje van Zuiden ¹, Konstantina Delli ¹, Alja Stel ¹, Bert van der vegt ¹, Erlin Haacke ¹, Lisette Olie ¹, Leonie Los ¹, Gwenny Verstappen ¹, Sarah Pringle ¹, Fred Spijkervet ¹, Frans Kroese ¹, Arjan Vissink ¹, Suzanne Arends ² and Hendrika Bootsma ³, ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Abatacept (CTLA-4-Ig) targets the CD80/CD86:CD28 co-stimulatory pathway required for full T-cell activation and T-cell dependent activation of B-cells. The Abatacept Sjögren Active Patients phase…
Abstract Number: 2040 • 2013 ACR/ARHP Annual Meeting
Pilot Study Of Abatacept In Patients With Refractory Autoimmune Chronic Urticaria
Clifton O. Bingham III¹, Marilyn Towns¹ and Susan J. Bartlett², ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada
Background/Purpose: Associations between chronic urticaria (CU) with autoantibodies and other autoimmune conditions have implicated T cells in CU initiation and/or propagation. Many patients (pts) have…
Abstract Number: 522 • 2013 ACR/ARHP Annual Meeting
Abatacept Reduces Disease Activity In Early Primary Sjögren’s Syndrome:One Year Results From a Phase II Open-Label Study
PM Meiners¹, A Vissink², Fkl Spijkervet³, EA Haacke⁴, WH Abdulahad⁵, E Brouwer⁵, MG Huitema⁵, N Sillevis Smitt-Kamminga⁶, FGM Kroese⁷, S Arends⁵ and H Bootsma⁵, ¹Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁴Pathology, University Medical Center Groningen, Groningen, Netherlands, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁶Opthalmology, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Traditional DMARDs have limited effects in primary Sjögren's (pSS) patients. B cell depletion therapy with rituximab showed efficacy, but had some side-effects. T and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].